, /PRNewswire/ -- Ronovo Surgical, a -based medical technology innovator developing novel surgical robotics for soft tissue procedures, announces the successful closing of its Series B financing, raising a total of million from leading healthcare technology investors to accelerate the commercialization of its proprietary modular robotic system, the CarinaTM Platform, in the Chinese market and set the stage for international expansion. This round was co-led by Guolian Capital and INCE Capital, with participation from King Star Med LP and existing shareholder, LongRiver Investments. "Securing this round of financing from such an esteemed group of investors, despite challenging capital market conditions, is significant acknowledgement of our vision, mission and the execution of the team," said , CEO of Ronovo Surgical.
"Our innovation efforts for developing Carina have been laser-focused on expanding its application across multiple specialties, reducing learning curve, and improving cost-effectiveness." Carina features a modular architecture that simultaneously exemplifies clinical capability, flexibility, accessibility and affordability. It has been highly recognized and lauded by minimally invasive surgery experts across , US, and .
"Taking Carina from concept design to completion of human clinical trial in three years, is the result of our clinical-driven approach toward engineering, practicality in design decisions and the remarkable dedication of our team. " commented , CTO.
